Last reviewed · How we verify

Moderna mRNA-1273 COVID-19 vaccine

National Institute of Allergy and Infectious Diseases (NIAID) · FDA-approved active Biologic

Moderna mRNA-1273 COVID-19 vaccine is a mRNA vaccine Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 prevention.

mRNA-1273 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

mRNA-1273 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. Used for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 prevention.

At a glance

Generic nameModerna mRNA-1273 COVID-19 vaccine
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classmRNA vaccine
TargetSARS-CoV-2 spike protein (S protein)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine consists of messenger RNA encapsulated in lipid nanoparticles that deliver genetic instructions to host cells. These cells then synthesize the spike protein antigen, which stimulates both humoral (antibody) and cellular (T-cell) immune responses against SARS-CoV-2. This adaptive immune response provides protection against infection and severe disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moderna mRNA-1273 COVID-19 vaccine

What is Moderna mRNA-1273 COVID-19 vaccine?

Moderna mRNA-1273 COVID-19 vaccine is a mRNA vaccine drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 prevention.

How does Moderna mRNA-1273 COVID-19 vaccine work?

mRNA-1273 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

What is Moderna mRNA-1273 COVID-19 vaccine used for?

Moderna mRNA-1273 COVID-19 vaccine is indicated for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 prevention.

Who makes Moderna mRNA-1273 COVID-19 vaccine?

Moderna mRNA-1273 COVID-19 vaccine is developed and marketed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

What drug class is Moderna mRNA-1273 COVID-19 vaccine in?

Moderna mRNA-1273 COVID-19 vaccine belongs to the mRNA vaccine class. See all mRNA vaccine drugs at /class/mrna-vaccine.

What development phase is Moderna mRNA-1273 COVID-19 vaccine in?

Moderna mRNA-1273 COVID-19 vaccine is FDA-approved (marketed).

What are the side effects of Moderna mRNA-1273 COVID-19 vaccine?

Common side effects of Moderna mRNA-1273 COVID-19 vaccine include Injection site pain, Fatigue, Myalgia, Headache, Fever, Chills.

What does Moderna mRNA-1273 COVID-19 vaccine target?

Moderna mRNA-1273 COVID-19 vaccine targets SARS-CoV-2 spike protein (S protein) and is a mRNA vaccine.

Related